This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.Read Article
The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.Read Article
The revitalizing powers of sleep are numerous but what are the consequences to inadequate sleep? A current report in the Journal of Experimental Medicine shows the connection between sleep and immune function as measured in mice and humans; specifically, a good night’s sleep promotes normalRead Article
Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our websiteRead Article
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.Read Article
Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time.
The article appears in Nature Reviews Rheumatology and discusses worldwide varianceRead Article
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.
After historic drop in 2020 (COVID), life expectancy in USA dropped again,
Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.Read Article
Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessmentsRead Article
Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.Read Article
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
A population-based study examined 22,009,375 persons from the Clinical Practice Research Datalink (CPRD), GOLD and Aurum datasets. This includedRead Article
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.
This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.
CDC report of fungal infx in US 2019 - coccidioidomycosis (20,061), histoplasmosis (1,124) & blastomycosis (240
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE). This is not surprising as IL-2 is needed to bolster insufficient regulatory T cell (Treg) activity, thought to be pivotal to theRead Article
A cohort study of SLE patients shows that remission and low disease activity (LDA) are associated with less damage accrual over time.
Patients from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort were serially assessed with different measures ofRead Article
Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens (ENA) rarely changes the result or adds a new diagnosis.
This study from a single, multicentre tertiary health networkRead Article
MMWR recently reviewed the epidemiology and characteristics of U.S. monkeypox cases seen between May and July 2022. They found that 99% of cases occurred in men, 94% of whom reported recent male-to-male sexual or close intimate contact. Current outbreak-associated cases are less likely toRead Article
Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.Read Article
The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
This guideline builds on pastRead Article
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
D2T-RA is defined by failure of at least two different mechanism of actionRead Article
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.Read Article